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RUNX2 is a lineage-specific transcription factor (TF) known to promote cancer 
progression. However, the molecular mechanisms that control RUNX2 
expression in cancer remain widely unknown. Long non-coding RNAs 
(lncRNAs) are a novel class of transcripts that do not code for proteins and are 
often engaged in gene expression regulation. 
Using the ENCODE annotation data, we identified a previously uncharacterized 
family of lncRNAs within the RUNX2 locus, that we named RAIN (RUNX2 
Associated Intergenic Non-coding RNA). We showed that RAIN comprises 4 
major variants that share a common central region but differ at the 5'- and 3'- 
ends. The longest isoform (l-RAIN) is nuclear and strongly associated with 
chromatin, suggesting a role of RAIN in gene expression regulation. Expression 
analysis in cancer cell lines and patient samples demonstrated that RAIN 
correlates with RUNX2. Furthermore, RAIN silencing resulted in a significant 
RUNX2 repression demonstrating that this lncRNA is required for the 
expression of this TF in cancer. We showed that RAIN promotes RUNX2 
expression at least through two distinct mechanisms. Interacting with WDR5 
and directing its recruitment to the RUNX2-P2 promoter, RAIN modifies its 
transcriptional activation status, bursting transcription initiation. In parallel, 
RAIN sequesters NELFe preventing the binding of the NELF complex to the 
RUNX2 P2 promoter and restraining its inhibitory function on nascent 
transcripts elongation. Finally, we investigated the RAIN associated 
transcriptional profile in thyroid cancer showing that beside RUNX2, this 
lncRNA controls a panel of cancer associated TFs. Overall, our data 
characterize the function of a novel lncRNA and identify an additional layer in 
















































The Runt-related transcription factors (RUNX) belong to a family of metazoan 
transcription factors essential during development. The Runt gene was first 
identified in Drosophila melanogaster [1] as a transcription factor important for 
the development of the limbs, eye and antennae. In mammals, there are three 
proteins belonging to this family: RUNX1, also known as CBFA2 (Core-
Binding Factor subunit α-2), AML1 (Acute Myeloid Leukemia 1) and Pebp2αb 
(Polyomavirus Enhancer Binding Protein 2 subunit αb); RUNX2, also known as 
CBFA1, AML3 and Pebp2αa; RUNX3, also known as CBFA3, AML2 and 
Pebp2αc. In human, these genes localized on 21q22.12, 6p21.1 and 1p36.11, 
respectively [2-4]. 
The three RUNX genes share a common gene organization and a common 
protein structure likely since they arise from single gene duplications and 
functional diversification. In particular, they share a highly conserved Runt 
domain. This is a DNA binding domain of 128 aminoacids that recognizes a 
specific DNA sequence PyGPyGGTPy (Py=pyrimidin) and is essential for 
RUNX heterodimerization with the transcriptional co-activator CBFβ (Core-
Binding Factor β)/PEBP2β (Polyomavirus Enhancer Binding Protein 2 β) [5]. 
All RUNX factors have two alternative transcriptional starting sites, within two 
different promoters: the distal P1 promoter and the proximal P2 promoter. 
These promoters are selectively activated during development and give rise to 
two alternative proteins with different N-terminal. In addition, the RUNX 
factors share a carboxyl terminus (VWRPY) and present several activation 
domains (AD) and inhibitory domains (ID) that can interact with other 
transcription factors either with activatory or inhibitory functions [6;7] (Fig.1) 





Figure 1 The RUNX family structure RUNX genes have two promoters (P1 and P2), a 
common RUNT homology domain, activation and inhibition domain (AD/ID) and a VWRPY 
(Valine-Tryptophan-Arginine-Proline-Tyrosine) domain. 
 
For example, the RUNX2 AD/ID domain has been shown to interact with 
transcription promoting factors including YAP (Yes-Associated Protein) [9], 
HES-1 (Enhancer of Split-1) [10], MOZ (Monocytic leukemia Zinc finger) and 
MORF (MOZ-Related Factor) [11], or with repressor factors like HDAC6 




Figure 2 The RUNX family interaction landscape The RUNX family can interact with 
different targets belonging to several pathways; these can be functionally redundant and can 
impact on distinct transcriptional programs to regulate cell development, differentiation and 
proliferation. These pathways can be deregulated in cancer, promoting tumor aggressiveness 
and metastatization (Image from [23]). 
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In some cases, changes in one of the RUNX factor may alter the levels of the 
others. For example, in B cells RUNX1 and RUNX3 are inversely correlated 
[2]. As well an inverse correlation between RUNX2 and RUNX1 has been 
observed during skeletal development [24], while in breast cancer RUNX1 is 
inversely related to RUNX2 and RUNX3 [25]. 
 
RUNX2 
The human RUNX2 gene stretches 227.766 nucleotides on chromosome 6p21.1 
and the most represented splicing isoform consists of 8 exons. As all RUNX 
genes, it presents two major isoforms, starting from the two different 
promoters: the RUNX2 I-type (also called mesenchymal) is transcribed from 
the proximal P2 promoter and it originates a 507 aminoacids protein, while the 
RUNX2 II-type (also known as osteoblastic) starts from P1 and is translated in 
a 521 aminoacids protein [26]. These promoters are separately activated during 
different developmental processes and are able to generate two different 
proteins with different amino-termini: MASNS (Methionine-Alanine-Serine-
Asparagine-Serine) and MRIPV (Methionine-Arginine-Isoleucine-Proline-
Valine), respectively. In addition, both RUNX2 isoforms present a QA-rich 
(glutamine-arginine) domain, a NLS (Nuclear Localization Signal) and a 






Figure 3 RUNX2 structure The two RUNX2 isoforms share common domains to the other 
RUNX family members (RUNT domain, AD/ID and VWRPY motif) but present also peculiar 
domains. P1-isoform II present a MASNS motif at N-terminus, while the P2-isoform I have 
one less exon than RUNX2-II and have a MRIPV motif at N-terminus. The two RUNX2 
isoforms also share common domains: QA-rich motif, NLS and NMTS 
 
The expression of the two RUNX2 isoforms is finely regulated and highly 
dependent on the activity of the two promoters. The P1-derived isoform is 
mainly expressed throughout the entire bone morphogenetic process, from 
osteoblast precursors to mature osteoblasts and terminal differentiated 
chondrocytes, while the P2-derived isoform is more widely expressed. Its 
expression is enriched in early precursor of chondrocytes and osteoblasts [29] 
but also in non-osseous tissues, such as thyroid, breast, prostate and lung. 
Within the RUNX2 promoter sequence, there are several RUNX consensus 
binding sites implying that runx proteins are able to cross-regulate themselves 
and the other RUNX paralogues [8; 30-32]. 
RUNX2 expression is tightly regulated by different signaling pathways. 
A critical role in maintaining bone mass and in promoting osteoblast 
differentiation is played by the WNT (Wingless-type MMTV integration 
site)/LRP5 (low-density lipoprotein receptor related protein5)/β-catenin 
pathway [33-34]. Activation of the canonical WNT signaling lead to multiple 
events that induce TCF1 (T-cell factor 1) expression and the translocation of β-
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catenin into the nucleus where it forms a complex with TCF1 on the RUNX2 
promoter for its induction [35]. 
BMP2 (Bone Morphogenetic Protein 2) induces osteoblast differentiation and 
bone formation through ligation with its receptor and resulting Smad1/5/8 
phosphorylation and generation of a nuclear complex with Smad4 that is able to 
activate RUNX2 gene [36]. A similar signaling cascade is activated by TGFβ 
(Transforming Growth Factor β) [37]. On the other hand, TNF (Tumor Necrosis 
Factor) have a contrary effect on RUNX2 acting on MAPK (Mitogen-Activated 
Protein Kinase)/p38 signaling cascade leading to inhibition of osteoblast 
differentiation and to bone mass loosening [38-39]. 
RUNX2 is also regulated through post-transcriptional modifications, such as 
acetylation, sumoylation, phosphorylation and ubiquitination. RUNX2 
phosphorylation is usually mediated by ERK (Extracellular signal–Regulated 
Kinases)/MAPK cascades in the nucleus and can lead to positive [40] or 
negative [41-42] regulation. Even ubiquitination of RUNX2 is able to regulate 
its activity both positively [43] and negatively [44]. 
Finally, RUNX2 is regulated post-transcriptionally by both miRNA 
(microRNA) and small non-coding RNAs. Different studies have linked diverse 
miRNAs to RUNX2 activity in normal and in tumor cells; for example, mir-30a 
[45] and miR-103a [46] inhibit osteolysis through RUNX2 down-regulation; 
miR-204/211 regulates RUNX2 promoting adipogenesis and inhibiting 
osteogenesis of mesenchymal progenitor cells [47]. 
 
RUNX2 and cancer 
Several studies, including our [48], have linked the over-expression of RUNX2 
to tumor development and progression. Isoform I, encoded by the P2 promoter, 
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is by far the most prominent (and in epithelial derived cancer the solely) 
RUNX2 expressed isoform, being associated with development of 
osteosarcoma [49-50], prostate cancer [51], melanoma [52], ovarian cancer [53] 
and thyroid cancer [48]. Furthermore, many scientific evidence associate 
RUNX2 expression to bone metastatization in breast and thyroid cancer through 
TGFβ [54-55] and WNT pathways [35], in addition to estrogen signaling [56-
57]. 
Cancer cells that metastasize to bone are able to activate a genetic pathway 
similar to the bone cells one, this phenomenon is called “osteomimcry” 
(reviewed in [58]). The ability of RUNX2 to promote bone metastasis is 
associated to the induction of bone-related genes (BRGs [59]) leading to bone-
like phenotype of cancer cells. Bellahcène [60] and Kang [61] have previously 
demonstrated that breast cancer metastases present a specific gene signature, 
with the over-expression of BSP (Bone Sialoprotein), ALP (Alkaline 
Phosphatase), Col1A1 (Collagen 1α1) and OPN (Osteopontin) and other genes. 
RUNX2 is also the master-regulator of several genes associated to matrix 
degradation and cells motility [62], such as MMP-13 (metalloproteinase-13) 
and OPN [63]. Furthermore, RUNX2 is able to promote tumor angiogenesis by 
regulating factors such as VEGF (Vascular Endothelial Growth Factor) [64] and 
MMP-9 [65]. Thanks to its ability to regulate all these target genes, RUNX2 has 
been associated with tumor progression. Furthermore, RUNX2 over-expression 
has been linked to epithelial-mesenchymal transition (EMT) program, 
especially in breast and thyroid cancer [59; 66-67], which further underlines the 
contribution of RUNX2 to the acquisition of aggressive features and tumor 
progression. A previous study, in our lab, demonstrated that the expression of 




The oncogenic potential of RUNX2 has been also associated with the inhibition 
of p53 activity. Indeed, p53 is able to arrest cell cycle progression in G1/S 
and/or G2/M, if there is a repairable DNA damage, or to activate cells apoptosis 
if a severe DNA damage occurs [68-69]. Several studies have determined that 
RUNX2 inhibits apoptosis through Bcl-2 (B-cell lymphoma 2) induction [70] 
and neutralizing p53 [71] and p21 collaborating with HDAC6 [12;72]. 
Because of its role in cancer promotion, RUNX2 is a promising target for anti-
cancer strategies. Indeed, we have recently shown that the cytotoxic effects of 
epigenetic drugs like HDAC and BET (Bromodomain and Extraterminal Domain) 
inhibitors (HDACi and BETi, respectively) [73-74] are associated with a 
profound reduction of RUNX2 expression. Thus, understanding the molecular 
mechanisms that drive RUNX2 expression in cancer is important not only to get 
insights into the processes that support cancer progression but also to develop 
better strategies to counteract the activity of this transcription factor in cancer.  
 
Long non-coding RNAs (lncRNAs) 
In recent years, increasing evidence indicate that the non-coding genome plays 
fundamental roles in the regulation of coding-genes. In particular, in 2003 the 
US National Human Genome Research Institute (NHGRI) launched the 
ENCODE (Encyclopedia of DNA Elements) project, which involves research 
groups worldwide. This project aims to characterize all functional elements in 
the human genome; in 2007 they published the first results of their analyses 
[75]. One of the most exciting and surprising observation has been the wide 
transcriptional activity of the non-coding genome. They identified many non-
coding transcripts, comprising new regulatory elements and new transcription 
starting sites, overlapping protein-coding region and “silent” DNA region. 
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Long non-coding RNAs (lncRNAs) are molecules longer than 200 nucleotides 
that do not encode for proteins [76-78]. These transcripts share the same 
transcriptional biogenesis as the mRNAs, being transcribed by the RNA 
polymerase II (RNA-Pol II) and containing exons. They also have 5’ terminal 
methylguanosine cap and are frequently spliced and polyadenylated. By 
contrast, lncRNAs lack or have limited open reading frames (ORFs), are less 
expressed than mRNAs and display a higher tissue-specific expression pattern 
[79-80]. Furthermore, lncRNAs are poorly conserved during the evolution, even 
if they may present conserved secondary structures or short domains [81]. As 
for proteins, the identification of structurally conserved domains could 
represent a useful tool for the functional annotation and classification of these 
new molecules. However, differently from proteins, this seems to be a very 
difficult challenge for lncRNAs determined primarily by the high sequence 
heterogeneity and by the still limited information on their biological function. 
Several bioinformatic tools have been recently developed to identify potential 
domains able to mediate the functional interaction of lncRNAs with specific 
proteins. Some of them are derived from mRNA analyses, as MEMERIS 
(Multiple Em for Motif Elucitadion in RNA’s Including secondary Structures) 
[137], a tool that integrate information from sequence motif and secondary 
structure to unveil RNA binding proteins interaction, and GraphProt [138], a 
tool to unveil binding sites of RNA-interacting protein. Only a few software are 
specific for lncRNAs; one of them is based on the analyses of CLIP-seq data 
combined with RNA-seq and GWAS (Genome-Wide Association Study) data 
[139]. Nevertheless, the application of these tools is still limited and will surely 
be implemented when we will reach a more consistent knowledge on the 
lncRNAs’ domains functionality. Anyway, implementing these tools to further 
characterized lncRNAs would be very useful and it would be of great interest to 
make these tools easier for not-bioinformatic researcher. 
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LncRNAs can be transcribed from different functional elements in the genome. 
Actually, diverse non-coding transcripts originate from enhancers, promoters or 
intron regions. Otherwise, lncRNA can be named on the basis of their genomic 
localization; in particular, they can be intergenic, it means they are between 
protein-coding genes or gene-associated. Moreover, in this case, lncRNAs can 




Figure 4 The multiplicity of lncRNAs in mammalian genome LncRNAs divided on the 
basis of their transcription site, the sense of the transcription and the post-transcriptional 
processes. Abbreviation: lincRNA (Large Intergenic Non-coding RNA), NAT (Natural 
Antisense Transcript), eRNA (enhancer RNA), PROMPT (Promoter Upstream Transcript), 
sno-lncRNA (lncRNA with Small Nucleolar RNA ends), ciRNA (Circular Intronic RNA), 




LncRNAs are finely regulated at various levels: localization, chromatin state 
and post-transcriptional regulation works together to determine the cell-, tissue- 
developmental-, disease- state (reviewed in [83] and [84]). It is also known that 
lncRNAs are controlled at different levels of their genesis, maturation and 
degradation. Analysis of histone modification patterns have been largely used 
for the identification of active lncRNA-transcription sites. Similar to protein-
coding genes, actively transcribed lncRNA loci are enriched in H3K4me3, 
H3K9ac, H3K27ac. LncRNAs are subjected to special post-transcriptional 
processing different from those of mRNA and similar to the one of tRNA 
(transfer RNA): RNase P is able to cleave the 3'-termini of some lncRNAs, such 
as MALAT1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1) and 
NEAT1 (Nuclear-Enriched Abundant Transcript 1) to obtain mature lncRNA 
and to increase their stability [85]. One more mechanism include the 
stabilization of non-coding transcripts through the transcription of protein-
introns and the formation of sno-lncRNA: a lncRNA transcript, lacking 5'cap 
and polyadenylated, flanked by two snoRNAs (small nucleolar RNA). 
Another mechanism of lncRNA post-transcriptional regulation, is the 
circularization of some RNAs (circRNAs) that can also have sponge-like 
features to retain miRNAs, as CDR1as (Cerebellar Degeneration-Related 
protein 1 Antisense) which is able to retain more than 70 miRNAs [86]. 
 
Classification of lncRNAs 
The great effort in mapping functional elements within the genome lead to a 




Now a day, the number of identified lncRNA exceeds 30.000. Their wide 
number and high expression specificity, qualify lncRNAs as promising 
biomarkers in different diseases. Many annotation databases have been recently 
developed representing precious tools for the study of lncRNA biology. Beside 
the ENCODE project, which results were pivotal for the comprehension of 
genomic function, other databases relevant in the field of lncRNAs are 
FANTOM (Functional Annotation of the mammalian genome), GTEx 
(Genotype-Tissue Expression) and GENCODE (Encyclopædia of genes and 
gene variants). The FANTOM project, started in 2000, allocates functional 
annotations to the full-length cDNAs first in mouse [87] and later in 
mammalian [88-89]. This consortium intent is to identify and characterize the 
non-coding genome elements in different cells types, revealing what genome 
portions are actively transcribed during the development phases and cells 
differentiation. In 2017, FANTOM5 (fifth phase of the project) also generated a 
comprehensive atlas of more than 27.000 lncRNAs, with independent cell-type-
specific expression profiles, using a CAGE (5' Cap Analysis of Gene 
Expression) approach [90]. Moreover, also the GENCODE project keep on 
studying the human genome to integrate and expand human annotation from the 
ENCODE project [91], adding information on lncRNA expression, structure 
and function [79]. 
The massive amount of novel ncRNAs and their great variety make difficult 
their functional characterization, while their heterogeneity complicates their 
possible classification based on common features. Nevertheless, first attempts 
of classification for these molecules have been suggested. To simplify, non-
coding RNAs have been firstly categorized by their size: short non-coding RNA 
(less than 200 base pairs in length), including transcripts as snoRNAs, tRNA, 
miRNA, siRNA (short/small interfering RNA); and long non-coding RNA 
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(more than 200 base pairs in length), that includes, for example, lincRNAs, 
pseudogenes, ciRNAs and many others. Furthermore, lncRNAs have been 
stratified based on their genomic localization. These classifications are 
continuously updated, the categorization is not accepted worldwide, and the 







Figure 5 LncRNAs category Examples of classifications hypothesized on different 
characteristics (Image from: [92]). 
 
Enhancer-Associated lncRNAs 
For many decades, gene expression regulation has been considered as a mono-
dimensional process in which each gene was controlled by the activity of the 
nearest promoter. Systematic functional analysis of non-coding genome has 
revealed that gene expression requires a continuous and widespread regulatory 
landscape involving a specific genomic architecture and the hierarchical 
interactions of multiple interspersed regulatory elements. 
Many factors collaborate to regulate the gene expression, so that genes are 
expressed in the right place in the right moment [93]. Among all these, there are 
the enhancers (ENHs), DNA sequences containing multiple binding sites for 
transcription factors, RNA-PolII (RNA-Polymerase II) and co-factors. ENHs 
are able to activate transcription independently from their distance from the 
promoter and the strand orientation; they can also act on genes located on 
different chromosomes [94-95]. These genome elements can recruit 
transcription factors and bring them in contact to the gene promoter enhancing 
transcription through the formation of chromatin loops. 
In recent years, it has been observed that enhancers are also transcribed into 
non-coding RNAs. Whether these molecules contribute to the ENHs function is 
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still under debate. ENHs can be transcribed into two distinct classes of non-
coding transcripts: eRNA short RNA coded in both orientation or lncRNA 
called as ENH-associated lncRNA. In 2010 Kim TK and colleagues [96] and 
Ørom UA and colleagues [97] used genome-wide analysis and GENCODE to 
define features of ENH-Associated ncRNA. They showed that transcribed 
enhancers have peculiar chromatin marks, like high levels of RNA-PolII, 
binding of CBP (CREB-Binding Protein) and p300, H3K4Me1 high and 
H3K4Me3 low. Furthermore, they found that these lncRNAs were able to 
regulate in cis neighboring protein-coding genes as well as control genes in 
trans, that is the control of genes located far in the linear sequence of the 
genome. 
Currently, the main hypothesis about the role of these lncRNAs is that they 
serve as a chromatin hub interacting with other factors, such as histone 
modification complex and TFs. It has been demonstrated that lncRNAs are able 
to interact with WDR5 (WD Repeat Domain 5-a subunit of methyltransferase 
complex) to regulate genes activation [98-99]. 
Further, some of these lncRNAs exhibit also the role to stabilize the 
engagement between promoter and enhancers, interacting with Mediator 
complex [100] and cohesion [101]. 
Moreover, ENH-associated lncRNAs are able to assist the recruitment of TFs 
and to maintain them at their regulatory sites. For example, YY1 (Yin-Yang 1) 
is a transcription factor able to bind both promoter-/enhancers-associated 
elements and RNA transcribed from those, suggesting that these nascent RNAs 
can stabilize the engagement of this TF [102]. CCAT-1L (Colorectal Cancer 
Associated Transcript 1-long isoform) is an ENH-associated lncRNA, 
positively associated to MYC transcription, that interacts with CTCF (CCCTC-
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binding factor) modulating its binding to chromatin leading to correct looping 
of the locus [103]. 
Finally, recently evidence have proposed that eRNA may control also 
transcription elongation by sequestering and inhibiting the Negative Elongation 
Factor (NELF) complex. Acting as decoy for NELFe, the RNA-binding subunit 
of the NELF complex, eRNA restrains the binding of the NELF complex 
downstream to the gene TSS (Transcription Starting Site) relieving RNA-PolII 
pausing and activating transcript elongation. However, whether this is a 
common property for lncRNA is still to be defined [104]. 
 
Localization and function of lncRNAs 
LncRNAs are ubiquitously distributed in the cell compartments: they have been 
found to localize in cytosol, nuclear fraction or associated with chromatin; they 
can also shuttle between the nucleus to the cytosol. However, lncRNAs are 
more enriched in the nucleus rather than in the cytosol, differing from mRNA, 
that are more abundant in the cytosol [105-106]. LncRNAs and mRNAs differ 
also for the mechanism of degradation. Being mainly nuclear, lncRNAs are 
exposed to nuclear exosome and in minor degree to cytosolic nonsense-
mediated decay (NMD). Instead, mRNAs only head towards the ribosomes in 
the cytoplasmic compartment and are degraded by decapping and 5’-to-3’ 
exonuclease activity. 
LncRNAs can be cleaved to form other short RNAs, as miRNAs and siRNAs 
[107], or tRNAs [108] that are able to shuttle to the cytosol. 
The different localizations affect lncRNAs function. Furthermore, lncRNAs 
present binding-domain for DNA, RNA and proteins and the binding with 
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respective targets lead also to conformational changes. It has been demonstrated 
that presence of specific RNA motif lead to different localization: BORG 
(BMP2-OP1-Responsive Gene) is a lncRNA that present a pentamer sequence 
AGCCC and T or A at position -8 and G or C at -3 specific for nuclear 
localization [109]. 
LncRNA nuclear-localized/ chromatin-associated are often gene regulators. 
Indeed, lncRNAs are physically related to their genomic locus and make them 
able to exert their activity without been previously exported to the cytoplasm 
for post-transcriptional modification. In fact, lncRNAs are able to recruit 
histone modification complex to induce or inhibit specific genes both in cis or 
in trans [110]. For example, KCNQ1OT1 (Potassium voltage-gated Channel 
subfamily Q member 1 opposite strand/antisense transcript 1) is able to interact 
with histone modification complexes: G9a (also known as EHMT2-euchromatic 
histone lysine methyltransferase 2) and PRC2 (Polycomb Repressive Complex 
2), both presenting methyltranferase activity, to mediate specific silencing of 
gene during fetal development [111]. HOTAIR (HOX Antisense Intergenic 
RNA) is another lncRNA that is able to interact with two different histone 
modification complexes, PRC2 and LSD1 (Lys-Specific Demethylase 1), in two 
different domains: PRC2 with a domain located in 5’ and LSD1 with a 3'domain 
[112]. 
LncRNAs are also implicated in the organization of nucleus and subnuclear 
compartments, such as speckles and paraspeckles. In particular, speckles are 
nuclear bodies that contain pre-mRNA splicing factor; instead, paraspeckles 
have a relevant role in the modulation of mRNA and protein levels because they 
are able to sequester them into nuclear bodies. MALAT1 is a lncRNA localized 
in the speckles that indirectly interacts with pre-mRNAs through serine/arginine 
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(SR) RNA splicing proteins; its down-regulation reduce the recruitment of SR 
proteins [113] and affect alternative splicing [114]. 
NEAT1 is a lncRNA fundamental for the architecture of paraspeckles; its 
depletion lead to the disassemble of these structures [115]. 
 
LncRNAs in cancer 
A potential function for lncRNAs in human diseases has been proposed. Among 
these, lncRNAs associated to cancer is one of the best studied branch: more 
than 4900 papers about this, can be found in PubMed. This is due to the 
different roles and the multiple interactions that lncRNAs exhibit in cells, and 
due to the wide expression of these transcripts. 
As previously described, lncRNAs act as fine regulators of gene transcription 
and chromatin accessibility. So, rearrangements and activating/inhibitory 
mismatch could lead to aberrant expression and function of onco-suppressor 
and oncogenic genes. Basically, deregulation of cell cycle, chromatin and 
epigenetic state, changes in RNA/DNA/proteins interactions and in their 
activity, could induce neoplastic transformation leading to carcinogenesis.  
Many studies demonstrated that some lncRNAs are associated to specific 
cancer, while others are associated with several tumors originating from 






Figure 6 Examples of lncRNAs cancer-associated Red represents lncRNAs up-regulated in 
cancer compared to normal tissue, while blue represents lncRNA down-regulated in cancer 
(Image from [116]). 
 
Examples of the first group are PCGEM1 (Prostate-specific transcript 1) [117], 
PCA3 (Prostate Cancer gene 3) [118] and PRNCR1 (Prostate cancer Non-
Coding RNA 1) [119] that are expressed only in prostate cancer; thanks to their 
specificity they have been proposed as markers for prostate cancer progression. 
MALAT1 belongs to the second group, lncRNAs that has been found to be 
associated with different tissues: lung, both early-stage of NSCLC (Non-Small 
Cell Lung Cancer) [120] and adenorcinoma [121], bones [122], colon [123] and 
other cancer sub-types. 
HOTAIR is another lncRNA associated with different tumor types, e.g. liver 




Furthermore, some lncRNAs are associated with metastasis or more aggressive 
cancer, but not with normal tissue or low-grade cancer. For example, HULC 
(Highly Upregulated in Liver Cancer) is a lncRNA highly expressed in liver 
metastasis of CRC (Colorectal Cancer) and in hepatocarcinoma, but not in 
primary CRC or in non-liver metastasis [128-129]. 
Due to their relevance in the biological and clinical field, lncRNAs have been 
proposed as diagnostic/prognostic biomarkers (reviewed in [130] and [116]), as 
PCGEM1 and PCA3. In addition, considering their importance in tumor onset 
and development, some lncRNAs have been proposed as therapeutic targets for 
the design of new therapies. Up to now there are four clinical trials that are 
enrolling patient in studies from Phase 1 to Phase 3, that set to use lncRNA as 
biomarker of drug response and to progression of disease. 
 
RAIN: a novel RUNX2 Associated Intergenic non-coding RNA 
We have previously demonstrated that the major RUNX2 isoform expressed in 
cancer cells is the isoform I, transcribed form the proximal-promoter P2 and 
that its overexpression promotes aggressiveness and metastatic potential of 
cancer cells [48]. However, we also showed that the P2 promoter is an indolent 
region and does not contains the elements required for the high levels of 
expression of RUNX2 in cancer.  
To unveil the molecular mechanisms that lead to deregulation of RUNX2 in 
cancer, we recently identified three previously uncharacterized RUNX2 ENHs 
downstream to the P2 promoter: ENH3, ENH11 and ENH13 [74]. Being aware 
of the ability of active ENHs of being transcribed into lncRNA we searched the 
ENCODE annotation data to discover RUNX2 associated lncRNA. Several 
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potential transcripts were described downstream of the RUNX2 locus, 
overlapping with the regions of the RUNX2 ENH11-ENH13 (Fig.7). 
 
 
Figure 7 Genome Browser image with ENCODE data Focusing on ENCODE data 
downstream of RUNX2 locus, there are several predicted non-coding transcripts within the 
enhancer region that we have characterized. 
 
However only one of these predicted molecules (TCONS00011820) was 
expressed in thyroid and mammary cancer cells. The annotate transcript was 
short and formed by two exons. Using a 5'- and 3'-RACE approach, we mapped 
the full length of this transcript in TPC1 cells. We found 4 major transcripts that 
presented a widely variable central region, two different starting sites, located in 
correspondence of the ENH10 and ENH11, and two different 3' end, a short and 
a long one. The long isoform is 3010bp longer than the short isoform. We 








Figure 8 RAIN full transcript characterization RACE approach using TCONS00011820 as 
template to find the full transcript. RAIN family is composed of four members with a common 
central region (grey) and two different 5’- and two different 3’-ends. 5’-ends are within 
previously identified ENH 10 and 11; 3’-ends differ for about 3000bp of length. 
 
RUNX2 and RAIN are co-regulated 
We have previously demonstrated that RUNX2 enhancers are binding sites for 
different transcription factors, and the master regulator of ENH3, ENH11 and 
ENH13 is c-Jun [74]. Furthermore, RAIN’s TSS are within RUNX2 ENH 
regions, in particular, correspond to ENH10 and ENH11. So, we wanted to 
determine if RUNX2 and RAIN can be regulated by the same elements. 
We used siRNA approach and the use of a dominant negative (DN) c-Jun 
plasmid to interfere with this TF. 
With both systems, we observed that RUNX2 and RAIN expression was down-





Figure 9 RUNX2 and RAIN expression quantification after c-Jun downregulation a-b) 
TPC1 cell line was transfected with increasing concentration (100ng and 20ng) of c-Jun 
dominant negative (DN) plasmid and RNA was extracted. RUNX2 (a) and RAIN (common) 
(b) expression was quantified by qRT-PCR, c) TPC1 cell line was reverse transfected with 
25nM of siRNA against c-Jun and after 24h RNA was extracted and the expression of RUNX2 
and RAIN was quantified by qRT-PCR. * p-value<0.05 
 
 
BET proteins are a family of protein that interact with acetylated histones to 
recruit histone acetylation complex to enhance the protein-coding gene 
transcription. In particular, BRD4 (Bromodomain 4) present a major role in 
control of distal enhancer regions, especially in cancer. A recent study, has 
demonstrated that BET-inhibitor drugs, such as JQ1, are able to antagonize the 
synthesis of non-coding eRNAs [131]. We wanted to confirm this hypothesis on 
our ENH-associated lncRNA, even because we have previously demonstrated 
that JQ1 treatment lead to repression of RUNX2 expression [74]. We treated 
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TPC1, BCPAP, MCF7 and MDA-MB 231 cells with 1µM of JQ1 and we 
extracted RNA. The quantification of the expression of RAIN showed that the 




Figure 10 RAIN expression after JQ1 treatment TPC1, BCPAP. MDA-MB231 and MCF7 
cell lines were treated with 1µM of JQ1. After 24h RNA was extracted and the expression of 
RAIN (common) was quantified by qRT-PCR. * p-value<0.05 
 
 
All these observations suggest a possible relevant function of RAIN in 
















































We have recently discovered RAIN (RUNX2 Associated Intergenic Non-coding 
RNA) a new ENH-associated lncRNA within the RUNX2 locus; we have, also, 
observed that RAIN and RUNX2 are co-regulated. 
The aim of this project was to characterize the function of RAIN, its interplay 
with RUNX2 and its potential relevance in cancer. We performed our analysis 
on a panel of different cancer cell lines, focusing on thyroid and breast tumor 
cell lines. In fact, in these tumor types, RUNX2 has been shown to be a marker 
of aggressiveness and its overexpression has been correlated with progression 
and metastasization. 
First, we characterized the functional interaction between RAIN and RUNX2 
promoter and enhancers with the intent of defining the effect and the 
mechanism of action of this lncRNA on RUNX2 expression regulation in the 
context of cancer cells. Finally, using RNA-Sequencing approach, we 
investigated the possibility that RAIN have other targets beside RUNX2 in 















































Thyroid cancer cell lines (BCPAP, TPC1, WRO, 8505C, CAL62) were obtained 
from Prof. Massimo Santoro (University of Naples, Naples, Italy); FTC-133 
(Thyroid follicular carcinoma cell line) were purchased from Sigma-Aldrich; 
SW579 (Thyroid papillary carcinoma cell line) were purchased from ATCC. All 
cancer cell lines were cultured at 37°C/5% CO2 in DMEM (Life Technologies), 
supplemented with 10% FBS (Life Techinologies) and 1% penicillin-
streptomycin (Life Technologies). 
Breast cancer cell line MDA-MB-231 was obtained from Dr. Adriana Albini 
(Scientific and Technology Pole, IRCCS MultiMedica, Milan), MCF7 was 
obtained from Dr. Massimo Broggini (IRCCS-Istituto di Ricerche 
Farmacologiche Mario Negri, Milan, Italy), ZR-75-1 were obtained from Prof. 
Bertolini (IEO, Milan, Italy) and HCC1428 were purchased from ATCC. Breast 
cancer cell lines were cultured at 37°C/5% CO2 in RPMI (ZR-75-1, HCC1428) 
or DMEM (MDA-MB-231, MCF7) supplemented with 10% FBS and 1% 
penicillin-streptomycin. 
NCI-H1299, A549, NCI-H1650, NCI-H1975 (lung adenocarcinoma cell lines) 
were purchased from ATCC and cultured at 37°C/5% CO2 in RPMI (Life 
Technologies) supplemented with 10% FBS and 1% penicillin-streptomycin. 
LNCap, PC-3, DU145 (prostate cancer cell lines) were obtained from ATCC 
and were cultured at 37°C/5% CO2 in RPMI (PC3 and LNCaP) or DMEM (DU 
145) supplemented with 10% FBS and 1% penicillin-streptomycin. 
 
Patient samples 
52 fresh frozen patient samples, comprising 26 couples of matching normal and 
tumor tissues, were obtained from the Research Tissue Biobank of Arcispedale 
Santa Maria Nuova-IRCCS of Reggio Emilia after written informed consent 
obtained from all the patients involved in this project. The project was approved 
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by the local Ethical Committee (protocol no.: 2014/0014425 of 06/05/2014). 
 
RNA isolation and qPCR Assays 
Cell lines RNA samples were extracted using Trizol (Ambion) protocol and 
DNase (Roche) digestion was performed during purification of RNA samples. 
Patient tissues RNA samples were extracted using Trizol and further purified 
with RNeasy extraction kit (Qiagen) following the RNA clean up protocol and 
performing on-column DNase (Qiagen) digestion. 
Subsequently, cDNA was prepared by reverse transcription using the iScript 
cDNA kit (Bio-Rad); quantitative Reverse Transcription-PCR (qRT-PCR) was 
conducted using Sso Fast EvaGreen Super Mix (Bio-Rad) in the CFX96 Real 
Time PCR Detection System (Bio-Rad). 
The Real-Time protocol used is: 98°C for 2’; [98°C for 2”, 59°C for 5”] 
repeated for 40 times, followed by melting curve production: from 70°C to 
95°C with an increment of 0.5°C, and 1” of plate read. 
Primers sequences are listed in the table below. 
 
Protein extraction and western blot 
Total proteins were extracted with Passive Lysis Buffer (Promega) 
supplemented with a cocktail of protease inhibitors (Roche). Protein amount 
was quantified by Bradford (Bio-Rad) reagent. 15µg of proteins were loaded on 
any Kd SDS-PAGE gel (Bio-Rad). The proteins were transferred to 
nitrocellulose filters using the Trans-Blot Turbo Transfer System (Bio-Rad); 
after blocking with 5% milk (Bio-Rad)/PBST (PBS, with 0.1% Tween-20 
(Sigma-Aldrich)), membranes were stained with primary antibodies over night 
at 4°C, while secondary antibody staining was performed for 1 hour at room 
temperature. Primary antibodies used were mouse anti-α-Tubulin (Santa Cruz, 
sc-8035), mouse anti-RNA Polimerase II (Abcam, ab817), anti-NELFe (F-9, 
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SC377052 SCBT) and anti-β-actin (A1978 Sigma-Aldrich) while the secondary 
antibody was Mouse IgG HRP-Linked Whole Ab (GE Healthcare, NXA931). 
 
RACE (Rapid Amplification of cDNA Ends) 
RAIN full transcripts were determined performing 5΄ RACE and 3΄ RACE 
through the SMARTer RACE 5′/3′ (Clontech) kit following the producer's 
instructions. Briefly, 1 μg of TPC1 cells' DNAse-treated RNA was retro-
transcribed to generate 5′ RACE-ready and 3′ RACE-ready cDNA. 5′-ends and 
3′-ends of RAIN transcripts were amplified using specific primers and a 
touchdown PCR program. Amplified fragments were extracted from agarose 
gel, cloned into the pRACE plasmid and sequenced. 
 
Cells fractioning 
Cells were fractionated to obtain cytosol, nucleus and chromatin fractions. 
Briefly, cells were harvested and washed twice with PBS (Sigma-Aldrich). 
Cells were resuspended in PBS and divided in three Eppendorf tubes and 
spinned at 3000rpm for 5’ at 4°C; PBS was removed and cells were 
resuspended in Lysis Buffer (Promega) and protease inhibitor cocktail 
(bimake.com) to obtain total protein lysate, Trizol  to obtain total RNA, or 
Cytosol Buffer (10mM HEPES pH7.9, 1.5mM MgCl2, 10mM KCl, 0.5% NP-
40, RNase inhibitor, protease inhibitor) for further processing. Cells were 
incubated with Cytosol Buffer for the appropriate time for each cell line (8’ 
MCF7 and TPC1; 4’ MDA-MB 231; 2’ BCPAP) and spinned for 2’ at 4°C. The 
supernatant was collected in two different Eppendorf tubes (cytosolic protein 
and RNA), centrifuged for 15’ at 3000rpm to eliminate nuclear debris and 
transferred in two new Eppendorf tubes. Trizol was added to the RNA sample. 
The pellet was washed three times with Wash Buffer (10mM HEPES pH7.9, 
1.5mM MgCl2, 10mM KCl, RNase inhibitor, protease inhibitor) at 3000rpm for 
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2’ at 4°C. Then, the pellet was resuspended in Nuclear Buffer (20mM HEPES 
pH7.9, 25% glycerol, 0.42M NaCl, 1.5mM MgCl2, 0.2mM EDTA (Sigma-
Aldrich), RNase inhibitor, protease inhibitor) on ice for 30’ with frequent 
vortexing; after incubation, pellet was spinned at 14500rpm for 10’ at 4°C and 
supernatant was divided in two Eppendorf tubes to obtain nuclear protein and 
RNA. Trizol was added to extract nuclear RNA. The chromatin-containing 
pellet was resuspended in Trizol and further processed. 
At least three biological replicates were conducted for each cell line. 
 
Small interfering RNA (siRNA) and gapmeRs transfections 
Select siRNA interference oligos against RAIN (common locus), NELFe, c-Jun 
and negative control oligos (Ambion) were used for transfections. GapmeRs 
against RAIN (targeting specifically the long isoforms) and negative control 
(Exiqon), both comprising LNA nucleotides, were used to specifically silence 
the RAIN long isoforms. Transfections were performed using the RNAiMax 
Lipofectamine (Thermo Fisher Reagent) reagent using the reverse transfection 
following the manufacturer’s protocol. Briefly, RNAiMax, Opti-MEM (Life 
Technologies) and 25nM of siRNA or gapmeRs were prepared and incubated 
for 20’; cells were harvested, resuspended in medium without antibiotics, and 
added to transfection reagents in culture plates. Next day, medium was replaced 
with complete fresh medium. Cells were harvested and analyzed 24 or 48 hours 
after transfection. GapmeRs and siRNA oligos sequences are indicated in the 
table below. 
 
Plasmid vectors and transfection 
c-Jun DN (Dominant Negative) expressing vector was kindly gifted by Dr. 




Cells were transfected with increasing concentration of c-Jun or empty vector 
using Lipofectamine 2000 (Thermo Scientific) following procedure's protocol. 
Briefly, TPC1 were plated at 70% of confluence in 24-well plate, next day 
increasing dilutions (100ng and 20ng) of plasmid vector or empty vector, were 
diluted in Opti-MEM medium and then lipofectamine 2000 was added. After 
20' of incubation, reagents were added to the cells' medium (complete medium 
without antibiotics). After 48h hours cells were detached and further analyzed. 
 
Cell proliferation assay 
24 hours after cells transfection, 2x103 cells for each cell line were seeded in 
triplicate in a 96-well plate in regular growth medium. Viable cells were 
counted every 24 hours for 4 days using trypan blue staining and Burker 
chamber. Three biological replicates were conducted for each cell line. 
 
Scratch wound healing assay 
24 hours after reverse transfection, each cell line was seeded at 70% confluence 
in a six-well plate. Next day, scratches were applied after cell adhesion by using 
a pipette tip. Healing areas were photographed at different time-point (0, 6 
hours, 12 hours and 24 hours) and measured using ImageJ software. Three 
biological replicates were conducted for each cell line. 
 
Analysis of mRNA stability 
Actinomycin D (Sigma-Aldrich) was used to inhibit nascent RNA synthesis. 
6x104 cells/well (MDA-MB 231) or 5x104 cells/well (TPC1) were seeded in 
each well of a 24-well plate and were treated with 5 μg/ml actinomycin D or 
DMSO (Sigma-Aldrich). Samples were collected at the time of treatment and 




Fluorescence in situ hybridization 
For in situ hybridization, 1.5x105 cells were plated on a coverslip in each well 
of a 6-well plate; next day, cells were washed twice shortly with PBS. Cells 
were fixed for 10' with 4% PFA (paraformaldehyde, Santa Cruz) at room 
temperature. Cells were washed three times for 5' with PBS and rinsed once 
with ice cold 70% EtOH (Carlo Erba); then, ice cold 70% EtOH was added and 
cells were kept at -20°C for at least one night. On the next day, cells were 
rehydrated by washing twice with PBS for 5' each. Cells were permeabilized 
with permeabilizing solution (0.5% triton X-100 (Sigma-Aldrich) in PBS, 
RNase inhibitor) for 10' at room temperature with gentle swirl. Cells were 
washed three times for 5' with PBS and twice for 5' with 2xSSC,0.05% 
tween20. 
Coverslips were incubated with blocking solution (1% BSA (Sigma-Aldrich), 
2xSSC, 0.05% Tween 20) for 30' at room temperature in a humid chamber. 
Probes containing LNA nucleotides (Exiqon) were diluted to 50nM in 
hybridization buffer (50% deionized formamide (Carlo Erba), 2xSSC, 50mM 
Sodium phosphate pH 7 (Sigma-Aldrich), 10% dextran sulphate (MW>500,000 
Alfa Aesar)) and added to each coverslip. Then, coverslips were incubated in 
HYBrite Genetic Analysis System (Abbott Laboratories) for 2' at 80°C 
followed by 1 hour at 57°C (negative control) or 54°C (positive control and 
RAIN probes) to denature nucleic acids, as indicated in the datasheets. 
After incubation, coverslips were washed twice for 30' at 37ºC, with a pre-
warmed wash solution (50% formamide, 1x SSC, 0.025% Tween 20, pH 7.0); 
then, coverslips were washed twice for 5' at 37ºC, and once at room 
temperature, with 2x SSC, 0.05% Tween 20. 
Anti-digoxigenin (Abcam ab420) diluted 1:1000 (1µg/ml) in TNB buffer 
(100mM Tris-HCl pH 7.5, 150mM NaCl (Sigma-Aldrich), 0.5% BSA), was 
incubated in a dark humid chamber, at room temperature, for 30'. Then, 
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coverslips were washed three times for 5' with 2x SSC, 0.05% Tween 20 at 
room temperature. 
Anti-mouse immunoglobulin Alexa488 (Thermo Fisher Reagents A11001) 
diluted 1:1000 (1µg/ml) in TNB, was incubated in a dark humid chamber, at 
room temperature, for 30'. Then, coverslips were washed twice for 5' with 2x 
SSC, 0.05% Tween 20 at room temperature. 
Coverslips were stained with DAPI (D9542 Sigma-Aldrich) 1:1000 (1µg/ml) in 
TNB for 5' at room temperature; then the coverslips were washed shortly with 
PBS and mounted using SlowFade Gold antifade (Invitrogen). 
Three biological replicates were conducted. 
Probes sequences are listed in the table below. 
 
ChIRP (Chromatin Isolation by RNA Purification) 
ChIRP was performed following the protocol of Chu et colleagues [132] with 
minor adaptations. Eight biotin 3'-end TEG probes (Eurofins Genomics), 
matching the 3'long locus of RAIN, were used for the experiment; eight 3'- end 
biotin TEG probes against LacZ transcript (Eurofins Genomics) were used as 
negative control. Probes sequences are listed in the table below. 
Briefly, 4x107 cells were collected and divided in four different tubes and 
crosslinked for 10' at room temperature with 1% glutaraldehyde (Carlo Erba) in 
10ml of final volume. Cross-linking reaction was quenched with 1.25 M 
glycine (Sigma-Aldrich) at room temperature for 5' and cells pellet was washed 
twice with ice-cold PBS and flash-frozen at -80°C. Next, pellet was thawed and 
resuspended in Lysis Buffer (50mM TRIS-Cl pH7.0, 10mM EDTA, 1% SDS 
(Sigma-Aldrich)) supplemented with RNase inhibitors and protease inhibitors. 
Cells were sonicated for 4 times: each time was composed of 10 cycles 30” 
ON-30” OFF in water sonicator Bioruptor Pico (Diagenode). To avoid different 
rates of sonication in the different tubes, lysates were pooled together every 10 
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cycles and redistributed into original tubes to ensure homogeneity. After 
sonication, lysates were centrifuged for 10 minutes 13000rpm at 4°C to clarify 
the lysate and 2% RNA and 2% DNA input were taken. Then, 1ml of chromatin 
was supplemented with 2ml of hybridization buffer, RNase inhibitor, proteinase 
inhibitor and 1.5µl of 100pmol/µl probes. The mix were incubated for 4 hours 
at 37°C with shaking. After incubation, 100µl of magnetic beads (C1 magnetic 
beads, Invitrogen) were added and incubated for 30' at 37°C with shaking. After 
that, beads were washed five times with wash buffer using Magna GrIP 
magnetic strip (Millipore) to separate beads from supernatant. At last wash, 
well resuspended beads were divided into 100µl for RNA isolation (10% of 
volume) and 900µl for DNA isolation (90% of volume). 
RNA purification: Proteinase K buffer (100mM NaCl, 10mM TrisCl pH 7.0, 
1mM EDTA, 0.5%SDS, 5% proteinase K (Promega 20mg/ml)) was added to 
100µl of bead samples and RNA input for 45' at 50°C with end-to-end shaking; 
then, after centrifugation, samples were boiled for 10' at 95°C, chilled on ice 
and Trizol was added. Further, RNA extraction protocol with Trizol was 
followed and RNA was extracted with miRNeasy kit following procedure’s 
protocol. 
DNA isolation: bead samples and DNA input were supplemented with 10µl 
RNase A (10mg/ml) (Thermo Scientific) and 10U/µl RNase H (Thermo 
Scientific) per ml of DNA elution buffer (50mM NaHCO3, 1% SDS) and 
incubated for 30' at 37°C with shaking. After, the supernatant derived from 
beads IPs was kept using Magna GrIP. A second round with RNAse A and H 
step was performed on beads and DNA input and supernatant derived from 
beads IPs was separated using Magna GrIP and collected with the previous. 
Collected supernatant and DNA input were incubated for 45' at 50°C with 
shaking with 15µl of proteinase K. All the DNA samples were transferred to 
phase-lock gel tubes (Eppendorf) and phenol:chloroform:isoamyl (Carlo Erba) 
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was added and shaken for 10'. Then, samples were spinned and the aqueous 
phase was kept and supplemented with glycogen (Thermo Scientific) and 100% 
EtOH and stored overnight at -20°C. Next day, samples were spinned and 
supernatant was let decant. 70% EtOH was added, vortexed and spinned down. 
Supernatant was removed, and pellet was air dried, then resuspended in 30µl of 
Elution Buffer; samples were used for further qPCR analysis. 
Three biological replicates were conducted for each cell line. 
 
ChIP (Chromatin Immunoprecipitation) 
For Chromatin Immunoprecipitation, 4x106 cells were reverse transfected and 
plated in a 150mm (3.7x106) petri dish and in a well of 6-well plate (3x105) (to 
control RUNX2 down-regulation before performing ChIP assay). 48 hours after 
reverse transfection, cells were cross-linked in PBS with 1% formaldehyde 
(Sigma-Aldrich) solution for 10' in gentle rotation. Subsequently, they were 
treated with 2.5 M glycine for 5' to quench the cross-link. Cells were washed 
twice with PBS and scraped. After that, cells were collected in a tube and 
centrifuged for 5' at 4 °C. Cells were lysed in Cell Lysis Buffer (10mM Tris-
HCl pH 8.0, 85mM KCl, 0.5% NP-40) supplemented with Protease Inhibitor 
Cocktail for 10' at 4 °C. Nuclei were pelleted for 5' at 4 °C and pellet was 
incubated for 10' on ice in Nuclei Lysis Buffer (50mM Tris-HCl pH 8.0, 10mM 
EDTA, 10% SDS) supplemented with protease inhibitors. Nuclei were 
sonicated with 2 cycles 30” ON -30” OFF and cell debris were pelleted for 10' 
at 4°C. Lysate was diluted in ChIP dilution buffer (0.01% SDS, 1% Triton X-
100, 1.2mM EDTA, 16.7mM Tris-HCl pH 8.0, 167mM NaCl) supplemented 
with protease inhibitors and 10 µL were kept as input. Diluted lysate was 
divided and in each tube was added a different antibody and incubated 
overnight at 4°C in gentle rotation. Next day, Dynabeads Protein G (Invitrogen) 
were added and incubated at 4°C for 2 hours with gentle rocking. Then, the 
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beads were washed with Low salt wash buffer (20mM Tris-HCl pH 8.0, 
150mM NaCl, 0.1% SDS, 2mM EDTA, 1% Triton X-100) and with High salt 
wash buffer (20mM Tris-HCl pH 8.0, 500mM NaCl, 0.1% SDS, 2mM EDTA, 
1% Triton X-100). Subsequently, the beads were washed once with a LiCl 
solution (10mM Tris-HCl pH 8.0, 250mM LiCl, 1% NP-40, 1mM EDTA) and 
twice with TE Buffer (10mM Tris-HCl pH 8.0, 1mM EDTA). Elution was 
performed using Elution Buffer (0.5M NaHCO3, 10% SDS) added to each IP 
and incubated for 15' at room temperature with gentle rocking; elution was 
performed twice. 
Reverse cross-link was performed overnight at 65°C adding 12µL NaCl 5M. 
Samples were treated with 2µL proteinase K (10 mg/mL), 12µL EDTA (0.5M) 
and 6µLTris pH 6.5 (1M) for 1 hour at 45°C. 
DNA was isolated with PCR purification kit (Qiagen) following the 
manufacturer's protocol. Then, qPCR was performed. 
Antibodies used for ChIP were against H3K4me3 (Abcam-ab8580), H3K27Ac 
(ab4729-Abcam), RNA polymerase II phospho-S5 (ab5408- Abcam), total H3 
(ab180727, Abcam), WDR5 (A302-429A-bethyl) and NELFe (F-9, SC377052-
SCBT) IgG (as negative control, IgG mouse sc-2025-SCBT; IgG rabbit 2729-
Cell Signaling). 
Three biological replicates were conducted. 
 
RIP (RNA ImmunoPrecipitation) 
RIP was performed modifying Hendrickson et al. [133] protocol. 
Briefly, cells were collected and fixed in 0.1% formaldehyde (Sigma-Aldrich) 
solution for 10' with gentle rotation at room temperature. Cross-link was 
quenched with 0.125mM glycine for 5' with gentle swirl. Cells pellet was 
washed twice with PBS and resuspended in Nuclear Isolation Buffer (1.28M 
sucrose, 40mM Tris-HCl pH 7.5, 20mM MgCl2, 4% Triton X-100) 
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supplemented with protease and RNase inhibitors and kept on ice for 20’. After 
centrifugation, nuclei were resuspended in RIP Buffer (150mM KCl, 25mM 
Tris-HCl pH7.5, 5mM EDTA, 0.5mM DTT (Sigma-Aldrich), 0.5% NP-40) 
supplemented with protease and RNase inhibitors and sonicated for one cycle 
30"ON - 30"OFF. After sonication, nuclei debris were spinned and supernatant 
was kept. 10% of lysate were used for the input sample and 5x106 cells were 
used for each IP with 6µg of NELF-e (F-9, SC377052 SCBT), 4µg of WDR5 
(A302-429A, Bethyl) or BRD4 (A301-985A50, Bethyl) antibodies and the 
relative IgG control (mouse IgG SC2025 SCBT and rabbit IgG 2729S Cell 
Signaling). After overnight incubation with gentle rocking at 4°C, 20µl of 
Dynabeads protein G were added to each IP and incubated for 2 hours and 30' at 
4°C in rotating wheel. IPs were subsequently washed twice with RIP wash 
buffer (150mM KCl, 25mM Tris pH7.5, 5mM EDTA, 0.5% NP-40, 0.5mM 
DTT) supplemented with protease and RNase inhibitors. Reverse cross-link was 
performed adding to each IPs and input samples, diluted to 1X the 3X reverse-
crosslinking buffer (3X PBS (without Mg2+ or Ca2+), 6% N-lauroyl sarcosine 
(Sigma-Aldrich), 30mM EDTA), 15mM DTT (added fresh), 10µl of proteinase 
K and RNase inhibitors for 1 hour at 42°C and 1 hour at 55°C. Supernatant was 
collected by Magna GrIP magnetic separation, Trizol was added and RNA was 
isolated as previously described. 
At least three biological replicates were conducted for each cell line. 
 
RNA Sequencing and bioinformatic analysis 
For RNA-seq analysis, RNA was extracted using Trizol from cells pellet of 
TPC1 treated with gapmeRs against l-RAIN or control-Oligos and TPC1 treated 
with siRNA against RUNX2 or scramble. RNA quality and quantity were 
assessed by Bioanalyzer using Agilent RNA 6000 nano kit and by Nanodrop 
respectively. RNA-seq libraries were prepared using the TruSeq Stranded 
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mRNA Sample Preparation Kit (Illumina) starting from 1µg of RNA. Next 
generation sequencing was performed using NextSeq500 platform (Illumina). 
We loaded the pooled libraries in a 150 cycles High Output cartridge, in order 
to obtain a minimum of 20 million of sequencing reads for each sample 
replicate. 
The bioinformatic data analysis included sequence adapters removal, that was 
performed by Trimmomatic, quality checks, performed using FastQC, and RNA 
sequences alignment, performed using STAR. After that, reads count and 
normalization were conducted applying Cufflink RNA-Seq workflow. 
Differential gene expression was calculated by Cuffdiff pipeline as fold-change 
(TPC1 treated with l-RAIN gapmeRs vs control-Oligos and TPC1 treated with 
RUNX2 siRNA vs scramble). Genes with a p-value < 0.05 were considered 
significantly deregulated. Next, the results of these two analyses were merged, 
in order to identify genes specifically deregulated by l-RAIN or commonly 
affected by l-RAIN and RUNX2 down-regulation. Bioinformatic data analyses 
were performed using R software (version 3.4.2). RNA-seq results investigation 
was conducted by Kegg pathways enrichment analysis. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism Software (GraphPad). 














negative control Ambion cat.4390847 
RAIN common AAAGAAGUCAGUUAAAAUCAG 
NELFe Ambion cat.4392420 ID s15489 


























qRT-PCR primers   
RUNX2 F GTGCCTAGGCGCATTTCA 
RUNX2 R GCTCTTCTTACTGAGAGTGGAAGG 
RAIN common F CTCAAAGCAAGTCGCCAAAG 
RAIN common R CCTGTGATCTGCCCTTTAGC 
l-RAIN F TCTTTCTTTAGGGCTGTTATGG 
l-RAIN R AGGAGGAACACTGGGGTCTC 
l-RAIN RIP F ACCAAAAGGACATCTGCACA 
l-RAIN RIP R ACCTCCTAACCTTGCACACA 
Cyclophilin F GACCCAACACAAATGGTTCC 
cyclophilin R TTTCACTTTGCCAAACACCA 
GUSB F TTGAGCAAGACTGATACCACCTG 
GUSB R TCTGGTCTGCCGTGAACAGT 
XIST F GGCCAAGCTCCAGCTAATCT 
XIST R CGTCAAAGGGAATGGATCAC 
C-Jun F TGACTGCAAAGATGGAAACG 
C-Jun R CAGGTCATGCTCTGTTTCA 
NELFe F AAGTCAGGAGCCATCAGTGC 
NELFe R CTGGAAAGTGGGGACTGGTC 
WDR5 F AGTGCCTGAAGACGCTCATC 
WDR5 R TGGCGGCCAGGATGTATTTG 
CCNE2 F TGCAGAGCTGTTGGATCTCTGTG 
CCNE2 R GGCCGAAGCAGCAAGTATACC 
RUNX2 P2 F ACCATGGTGGAGATCATCG 
RUNX2 P2 R  GGCAGGGTCTTGTTGCAG 
enh3 F GCTGGGAAGATAGCCAAGAA 
enh3 R CCTTGCATCAGTTCCACAGA 
enh11 F CCCAAACCCCAAAGCAGAGA 
enh11 R CCCAAGTTCTCACCAGGCAT 
enh13 F GTGGAGTGGAGAGAGGAGAA 
enh13 R TGGCTTCATCTCACCCTCAG 
ctrl- ChIP F TCTCAAGGTGCCTGTCTGC 
ctrl- ChIP R TGAAGTTTGGCCTCTGGTCT 
MALAT1 F TGTTGGCACGAACACCTTCA 
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MALAT1 R TGGCCTACTCAAGCTCTTCTG 
KCNQ1ot1 F GGCTACGCCACAGGTGAAA 
KCNQ1ot1 R GTCTGCTGGCTTGTGTGTTG 
5.8S F GGTGGATCACTCGGCTCGT 
5.8S R GCAAGTGCGTTCGAAGTGTC 
GAPDH F CAATTCCCCATCTCAGTCGT 
GAPDH R GCAGCAGGACACTAGGGAGT 
- 1100 RUNX2 TSS F CGCTCCTTCATCCTCTCGAC 
- 1100 RUNX2 TSS R AAAATGCTTCCGTGGCTGT 
- 500 RUNX2 TSS F CTCTCTGGTGTCTCGGCTTC 
- 500 RUNX2 TSS R CAGACTAGGGGCAATCTCGC 
TSS RUNX2 F TGGACTGCTGAACCCACAC 
TSS RUNX2 R TGAGTTTGCAGCTTGGAATG 
+700 RUNX2 TSS F ACCATGGTGGAGATCATCG 
+700 RUNX2 TSS R GGCAGGGTCTTGTTGCAG 
+1300 RUNX2 TSS F CTCTCACCCGCTTCCCTCA 















































RUNX2 and RAIN expressions are correlated 
Our preliminary evidence indicated that RAIN was co-regulated with RUNX2 
in both thyroid and breast cancer cells. Thus, to explore a potential correlation 
between these two transcripts, we analyzed their expression in a panel of 
epithelial cancer cell lines, including lung-, prostate-, breast- and thyroid-
derived cancer, which are the tumors in which RUNX2 has been shown to play 




Figure 11 RUNX2 and RAIN expression in cancer cell lines Quantification of the expression 
of RUNX2 (a) and RAIN (b) in epithelial cancer cell lines: lung (green- H1299, H1975, H1650, 
A549), prostate (blue- PC3, LNCaP, DU145), thyroid (red- 8505C, BCPAP, TPC1, CAL62, 




As shown in figure 11, RUNX2 and RAIN expression was significantly positive 







Figure 12 RUNX2 and RAIN correlation The graph shows the relative expression of 
RUNX2 and RAIN in a panel of cancer cell lines. 
 
We have previously demonstrated that RUNX2 overexpression is associated 
with cancer development and aggressiveness in thyroid cancer. We extracted 
RNA from 26 thyroid cancer patients and we compared RUNX2 and RAIN 
expression in normal and tumor tissue. RUNX2 and RAIN were both 
overexpressed in cancer tissue as compared with normal thyroid. Next, we 
correlated the expression of RUNX2 and RAIN in tumor samples. We 
confirmed that also in vivo the expression of these transcripts was significantly 




Figure 13 RUNX2 and RAIN expression in patient’s samples We compared the expression 
of these transcripts in normal and tumor samples of the same patient (a). We also assessed the 
correlation of RUNX2 and RAIN in tumor samples and we obtained a significant positive 




Analysis of RAIN stability 
ENH-associated lncRNAs are averagely stable transcripts, more stable than 
eRNA but less than the mRNAs to which they are associated. We assessed the 
stability of RAIN, along with RUNX2 and c-MYC mRNA stability, by treating 
TPC1 and MDA-MB 231 cell lines with 1µg/ml of actinomycin D to interfere 
with mRNA synthesis. We collected RNA at different time points: 0, 30', 2 
hours, 4 hours, 8 hours, 12 hours, 24 hours. We compared the expression of 
each RNA at each time point with the expression at the corresponding time 0. 
We observed that RAIN is less stable than RUNX2 but more stable of c-MYC 
which is known to be rapidly degraded (Fig.14). We used KCNQ1ot1 and 




Figure 14 RAIN stability The RNA stability has been evaluated through qRT-PCR analysis, 
administrating actinomycin D to cultured cells and extracting RNA at different time points. 
 
 
We also calculated the half-life rate of each RNA using linear regression 
analysis in GraphPad Prism Software. The half-life of RAIN was about 7 hours 
in TPC1 cells and 9 hours in MDA-MB 231, while RUNX2 half-life was 11 
hours and 13 hours, respectively (Fig.15). These differences were probably due 
to the different replication rate of the analysed cell lines (TPC1 cells are more 
actively proliferating than MDA-MB 231) and to the lower expression of RAIN 
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Figure 15 Half-life rate calculation 50% of RNA decay was calculated through linear 
regression analysis of relative expression of each RNA using GraphPad Prism software. 
 
 
RAIN long isoforms are chromatin-associated 
Because the different cellular localization of lncRNAs is associated with 
diverse function, we next investigated the subcellular localization of RAIN. To 
this end, we performed cell fractioning and separated cytosolic, nuclear and 
chromatin fractions. We performed western blot to ensure we have correctly 
separated the different phases. We controlled total RNA-PolII and α-Tubulin, as 
nuclear and cytosolic markers respectively. Then, we extracted RNA and 
analyzed RAIN distribution in the different fractions. We used two different 
primer pairs that recognized different regions of RAIN. One pair recognized the 
common central region and detected both the long and the short RAIN 
isoforms. The second pair was specific for the long isoform. The chromatin-
associated lncRNA XIST was used as control. 
Noticeably, the long RAIN isoform (l-RAIN) was largely enriched in the 
nuclear and chromatin fractions, while the short RAIN isoform distributed 


































































Figure 16 RAIN subcellular localization TPC1, MDA-MB231, BCPAP and MCF7 cell lines 
were fractionated, RNA and proteins were extracted in subcellular fractions and analyzed for 
the presence of RAIN. RAIN common means that qRT-PCR primers recognized the common 
central region, l-RAIN means that primers recognize only the long isoform. 
 
We confirmed this different subcellular localization in TPC1 cells, through 
fluorescent in situ hybridization, using two different probes: one recognizing 
the common region and one only the long isoform (fig.17). 
 
 
Figure 17 RAIN localization by in situ hybridization FISH analysis were performed to 
confirm the subcellular localization of RAIN in TPC1 cell line. RAIN-common means that 
probes recognize the common central region, while l-RAIN means that probes recognized only 
the long isoform. 
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Knockdown of RAIN impairs RUNX2 expression 
We showed that RAIN is a chromatin-associated lncRNA and that its expression 
correlates with RUNX2. Thus, we reasoned that RAIN may take part to 
RUNX2 regulation. To test this hypothesis, we used two different approaches: 




Figure 18 siRNA, gapmeRs and qRT-PCR primers localization siRNA probes were 
designed to recognize the common central region. While gapmeRs were designed to recognized 
only the long isoform because they are in the nucleus and gapmeRs are able to target nuclear 
lncRNA better than siRNA. Grey arrows indicate qRT-PCR primers that recognize common 




First, we used, siRNA to knockdown both short and long RAIN isoforms. The 
target RNA degradation mechanism of siRNA, is based on the perfect 
complementarity with target mRNA. SiRNA and target RNA coupled and are 
cleaved by RISC (RNA-induced silencing complex) in the cytosol. 
TPC1 and MDA-MB 231 cells were transfected with siRNA targeting RAIN 
common region or with scramble oligos, as control, and RAIN and RUNX2 
expression was assessed by qRT-PCR 24 hours after transfection. Noticeably, 






Figure 19 RAIN and RUNX2 expression after siRNA transfection TPC1 and MDA-MB 
231 cell lines were reverse transfected with 25 nM of siRNA against the common region. After 
24 hours of transfection, RNA was extracted and RAIN and RUNX2 expression was quantified 
by qRT-PCR. * p-value<0.05. 
 
 
Next, we used gapmeRs, oligos with nucleotide LNA (locked nucleic acid) 
modification, to target the long isoforms of RAIN. These oligos recognized and 
paired to target RNA recruiting RNase H, an endonuclease present both in the 
cytosol and in the nucleus, that selectively degrade RNA of the DNA-RNA 
heteroduplex. Using nuclear RNAse to degrade target RNA, gapmeRs should 
be more efficient than siRNA to target the chromatin-associated lncRNA. 
We transfected TPC1 and MDA-MB 231 with gapmeRs or scramble oligos and 
we observed a significant down-regulation of RAIN and RUNX2, with a more 
efficient downregulation of l-RAIN, that is the isoform associated with the 
chromatin (Fig.20). We also observed a consequent more effective 





Figure 20 RAIN and RUNX2 expression after gapmeRs transfection TPC1 and MDA-MB 
231 cell lines were reverse transfected with 25 nM of gapmeRs against the 3’-long region. 
After 24 hours of transfection RNA was extracted and RAIN and RUNX2 expression was 
quantified by qRT-PCR. * p-value<0.05 
 
 
To ensure that was the RAIN interference that lead to RUNX2 down-regulation, 
we also transfected our cells with siRNA against RUNX2 and we did not 
observe any difference in RAIN expression. 
 
l-RAIN interacts with RUNX2 locus 
Next, we investigated the mechanism by which RAIN controls RUNX2 
expression in cancer cells. First, we used ChIRP approach to define whether 
RAIN interacts with RUNX2 P2 promoter. To immunoprecipitate RAIN, we 
designed eight probes that mapped on the long 3'-end. As negative control, we 
designed eight probes that mapped on LacZ, which is not expressed in 
mammalian cells. We performed our experiments on both TPC1 and MDA-MB 
231 cell lines. After IP, regions specifically bounded to target RNA were 
measured by qRT-PCR. In both cell lines, RAIN significantly interacted with 
the RUNX2 P2 promoter in a region spanning from the TSS and exon 1, 700bp 
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downstream of the transcription starting site (Fig.21). Furthermore, we used 




Figure 21 ChIRP analysis of RAIN and P2 interaction TPC1 (a) and MDA-MB 231 (b) cell 
lines were used for ChIRP approach to demonstrate that RAIN was able to interact with the 
genomic locus of RUNX2. L-RAIN interacted with P2 promoter of RUNX2-isoform I: we 
mapped the interaction site between TSS and 700bp downstream of the TSS. Promoters of 
GAPDH and 5.8S were used as negative control. * p-value<0.05. 
 
 
The interaction was specific for RAIN probes, since RAIN was not 




Figure 22 ChIRP control TPC1 and MDA-MB 231 RNA was extracted, during ChIRP 
protocol, to evaluate the correct procedure, to exclude that the ChIRP probes recognize and 





l-RAIN interacts with WDR5 and NELFe 
LncRNAs have the ability to interact with histone modification complexes to 
regulate the transcription of protein-coding genes. WDR5 is a subunit of 
MLL1/MLL complex that mediate the trimethylation of Lys-4 of histone H3 
(H3K4Me3) and gene activation. 
We used a RIP approach to evaluate the interaction of l-RAIN with WDR5 on 
TPC1 and MDA-MB 231 cell lines. We observed that l-RAIN interacted with 
WDR5 in a significant manner, while it did not interact with BRD4. We used 
IgG as negative control (Fig.23). 
 
 
Figure 23 RIP approach to evaluate l-RAIN interaction TPC1 and MDA-MB 231 cell lines 
were used for RIP analysis to evaluate the potential interaction of l-RAIN with histone 
modification complex. IgG were used as negative control of assay. * p-value<0.05, n.s. means 
not-significative. 
 
As previously mentioned, NELF is a protein complex, that inhibits elongation 
promoting RNA-PolII pausing 0-60 nucleotides downstream of TSS, 
consequently inhibiting the transcription. It has been demonstrated that NELF 
can interact with eRNA, but the interaction with lncRNA it has been only 
hypothesized. Thus, we used RIP to test if RAIN was able to associate also with 
NELFe in TPC1 and MDA-MB231 cells. NELFe is the RNA-binding subunit 
of the NELF complex and its activity is critical for NELF function. We showed 
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that IPs with NELFe antibody resulted in a significant enrichment of l-RAIN 
indicating that this lncRNA can also interact with the NELF complex (Fig.24). 
 
 
Figure 24 RIP approach to evaluate l-RAIN interaction TPC1 and MDA-MB 231 cell lines 
were used for RIP analysis to evaluate the potential interaction of l-RAIN with NELFe. IgG 
were used as negative control of assay. * p-value<0.05 
 
 
Down-regulation of l-RAIN decreases the activation of P2 
Based on our data, we hypothesized that l-RAIN positive activity on RUNX2 
expression was mediated by the interaction with WDR5. To verify this 
hypothesis, we performed ChIP experiments on TPC1 cell line, after down-
regulation of l-RAIN through gapmeRs transfection. 
First, we investigated whether knockdown of l-RAIN affected the recruitment 
of WDR5 on the P2 promoter. As expected, WRD5 binding on the P2 promoter 
was significantly reduced upon l-RAIN_Kd (knock down) confirming that 
RAIN was required for the recruitment of this factor on the P2 promoter. Then, 
we assessed whether the inhibition of WDR5 by l-RAIN_kd had consequences 
on the transcriptional activity of the P2 promoter by assessing both H3K27 
acetylation enrichment and RNA-PolII phospho-5S binding. We examined this 
RNA-PolII modification because serine 5 phosphorylation is associated with 
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the initiation of transcription and it is associated with the transcription complex 
downstream of the TSS of the genes. As well, since WRD5 mediates 
trimethylation of H3K4, we also analyzed the amount of this modification on 
the P2 promoter 48 hours after l-RAIN_Kd, that is the time in which we 
observed the most efficient l-RAIN down-regulation. Noticeably, reduction in 
the levels of l-RAIN significantly reduced both the RNA-PolII phospho-5S 
binding and H3K27Ac levels on the P2 promoter; as well, the amount of 
H3K4me3 on the P2 promoter was reduced upon l-RAIN_Kd, while the overall 




Figure 25 ChIP analysis on P2 of RUNX2 after l-RAIN down-regulation We performed 
ChIP analysis on TPC1 cell line 48 hours after reverse transfection with 25nM of gapmeRs 
against l-RAIN. We focused on P2 promoter (primers are located 700bp downstream of the 




By contrast, l-RAIN_kd have not relevant effect on the chromatin organization of 






Figure 26 ChIP analysis on ENHs region of RUNX2 after l-RAIN down-regulation We 
performed ChIP analysis on TPC1 cell line after reverse transfection with 25nM of gapmeRs 
against l-RAIN. We focused on ENH3, ENH11 and ENH13 regions. 
 
 
We used ChIP approach also to evaluate the effect of l-RAIN down-regulation 
on NELFe interaction with RUNX2 P2. We divided the P2 locus to obtain the 













Figure 27 ChIP analysis on RUNX2 P2 to evaluate the interaction of NELFe TPC1 cell 
lines were reverse transfected with 25 nM of gapmeRs against l-RAIN and after 48hours we 
employ ChIP approach. P2 promoter region was subdivided to locate the region of interaction 
between NELFe and RUNX2. * p-value<0.05 
 
 
We observed that NELFe interact with RUNX2 TSS and that the l-RAIN 
downregulation lead to an increasing interaction of NELFe with this region. 
 
Down-regulation of NELFe leads to up-regulation of RUNX2 
Since we showed that l-RAIN can also interact with NELFe, we explored the 
effect of NELFe silencing on RUNX2 expression. If l-RAIN binding to NELFe 
restraining the inhibitory effect of the NELF complex on transcription 
elongation, we may expect that NELFe silencing is associated with a positive 
effect on RUNX2 expression. We used siRNA to down-regulate NELFe in both 
TPC1 and MDA-MB231. We controlled the efficacy of down-regulation both 





Figure 28 NELFe down-regulation We used siRNA approach to down-regulate NELFe in 
TPC1 and MDA-MB 231 cell line. We reverse transfected cells with 50nM of siRNA against 
NELFe and after 48 hours we extracted RNA and quantified RUNX2 and CCNE2 (positive 
control) expression. * p-value<0.05. 
 
We observed that the down-regulation of NELFe leads to the upregulation of 
RUNX2 confirming the hypothesis that RAIN may act as decoy of NELF 
complex restraining its function. CCNE2 (Cyclin E2), which expression 
requires NELFe, was used as control of the functionality of the assay. 
 
l-RAIN down-regulation affects cells’ migration and proliferation 
We demonstrated that l-RAIN is required for RUNX2 expression. Since 
RUNX2 over-expression in cancer cell is correlated with cancer development 
and progression, we hypothesized that RAIN may also affect aggressiveness of 
thyroid and breast cancer. In a previous work, we demonstrated that RUNX2 
silencing lead to impairment of migration and invasiveness of thyroid cancer 
cells and that its overexpression increased these phenomena [48]. Thus, we 
analyzed the effect of RAIN silencing on proliferation and migration of TPC1 
and MDA-MB231 cells. 
63 
 
We transfected cell lines with gapmeRs and count cells number every 24 hours, 
from 0 to 96 hours (Fig.29). 
 
 
Figure 29 Proliferation assay after l-RAIN down-regulation TPC1 and MDA-MB 231 cell 
lines were reverse transfected with 25nM of gapmeRs against l-RAIN and 24 hours later, cells 
were plated in 96-well plate. Every 24h hours cells were detached and counted. *p-value<0.05 
 
 
Transfected cells were also tested for their ability to wound healing in scratch 
test. Cells were photographed at 0, 6 hours, 12 hours and 24 hours (Fig.30). 
 
 
Figure 30 Wound healing assay after l-RAIN down-regulation TPC1 and MDA-MB 231 
cell lines were reverse transfected with 25nM of gapmeRs against l-RAIN and 24 hours later, 
cells were plated in 6-well plate. After cells attachment, we scratched the well and 
photographed the scratches at different time point. We measured the scratches and compared 
them to T0. * p-value<0.05. 
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RUNX2 and RAIN down-regulation and analysis of their interplay in 
down-regulated cells 
We have demonstrated that RUNX2 and RAIN are co-regulated and co-
expressed in cancer, both in vitro and in vivo. We have also demonstrated that 
RAIN interacts with WDR5 and NELFe to regulate the expression of RUNX2. 
Following these results, we wanted to assess if RAIN is able to regulate other 
pathways not associated with RUNX2. We performed two RNA-sequencing 
experiments to define the gene expression profile of cells in which either RAIN 
or RUNX2 were silenced. Comparing the expression profile of cells silenced 
for RAIN with the profile of scramble transfected cells, we identified a list of 
706 differentially expressed gene: 224 genes were up-regulated and 482 down-
regulated. As well, differential analysis of the gene expression profile of TPC1 
cells transfected with siRUNX2 or siCTRL identified 1754 gene of which 574 
were up-regulated and 1180 down-regulated. Merging these lists, we observed 
that 163 of the 706 RAIN target genes were also affected by RUNX2 silencing 




Figure 31 Diagrammatic representation of gene differential expressed in RNA-Seq 
analyses TPC1 cell line was reverse transfected with siRNA against RUNX2, gapmeRs 
against l-RAIN and control negative oligos. 
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We analyzed the list of RAIN-RUNX2 common genes using DAVID (Database 
for Annotation, Visualization and Integrated Discovery) searching for enriched 




Figure 32 KEGG pathway analysis on functional annotation enrichment We submit our 
163 differential-expressed genes on DAVID software and we focused on KEGG pathway 
functional annotation tool. 
 
 
We observed that “transcriptional misregulation in cancer” was the most 
enriched pathway in common genes. Genes belonging of this pathway are: 
BCL2A1, CXCL8, HIST1H3E, IGFBP3, IL1R2, RUNX2, SPINT1 and 
TGFBR2. Other pathways enriched in this analysis are correlated to tumor 
aggressiveness and tumor microenvironment involvement, as cytokine-cytokine 
receptor interaction, MAPK, TGF-β and NF-kB pathways. 
Among the 163 genes, 84 were down-regulated and 14 were up-regulated in 
both experiments. Focusing on genes down-regulated, we looked for the 
functional annotation on KEGG pathway and we obtained that the enriched 
pathways are “osteoclast differentiation” and “cytokine-cytokine receptor 
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interaction”, strengthen the hypothesis that these are direct-RUNX2 mediated 
targets. 
Next, we focused on those genes that resulted as RAIN specific (RUNX2 
unrelated) targets. Of the 543 RAIN target genes 65% were down-regulated and 
35% up-regulated, confirming an overall positive role of RAIN on gene 
expression. Of these genes 38 were on chromosome 6 and likely controlled in 
cis by this lncRNA. Among the 543 genes, there were also 9 long intergenic 




Figure 33 KEGG pathway analysis on functional annotation enrichment We submitted 
our 543 differential-expressed genes on DAVID software and we focused on KEGG pathway 




DAVID and KEGG pathway analyses (Fig.33) reveled that RAIN-associated 
pathways were related to transcriptional misregulation in cancer and other 
cancer specific pathways, including the FOXO, Hippo and Jak-Stat pathways. 
We decided to focus on “transcriptional misregulation in cancer” because of the 
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high expression of RAIN in tumor samples. Genes belonging to this group are: 
MMP3, MYC, ETV6, AFF1, PLAT, EYA1, CDKN2C, BCL6, ID2, JUP, HPGD, 
PAX5 and RUNX2. In particular, some of these genes were down-regulated 
after l-RAIN_kd even more that RUNX2, suggesting a role of RAIN in direct 




Figure 34 “Transcriptional misregulation in cancer” pathway enriched in l-RAIN_kd 
cells TPC1 cell line reverse transfected with gapmeRs against l-RAIN showed a differential 





Further investigation and validation is needed to evaluate the impact of RAIN 
on these other target genes. We also would like to confirm the indirect-RUNX2 
effects, down-regulating l-RAIN and expressing RUNX2 ectopically. However, 
these preliminary data suggest that the role of RAIN in cancer may be wider 




RAIN model of function 
Thanks to our results, we hypothesized a model of action that can explain the 
mechanism of RAIN regulation on RUNX2. 
RAIN is transcribed from RUNX2 ENH10 and ENH11 regions and it is able to 
interact with RUNX2 P2. Moreover, RAIN can recruit WDR5, bringing it in 
contact with the promoter of RUNX2-isoform I. WDR5 belong to the MLL 
complex that trimethylates H3K4 and enhance the transcription. Furthermore, 
RAIN can sequester NELFe, removing it to RNA-PolII. This detachment let the 






Figure 31 RAIN function model RAIN is transcribed from RUNX2 ENH10 and ENH11, then 
it collaborates to RUNX2 regulation interacting with WDR5 and NELFe enhancing RUNX2 















































Long non-coding RNAs are non-coding elements which are gaining attention 
for their relevance in gene expression regulation. However, due to the limited 
information on the mechanisms of action of these molecules their role in gene 
regulation remain an open question. Some have hypothesized that the act of 
transcription of lncRNA rather than their sequence is required for the 3D 
architecture of genome, and for the topological organization of transcriptional 
domains [134]. The limited number of lncRNAs that have been functionally 
characterized have been shown to regulate the recruitment of chromatin 
remodeling complexes or transcription factors affecting transcription both in a 
positive or negative fashion.  
Here we described RAIN, a novel family of lncRNAs, and we showed that not 
only its expression but also its specific functions are required to sustain RUNX2 
expression in cancer. Some of the previously characterized chromatin-
associated lncRNAs are able to interact with histone modification complex, in 
particular with members of Polycomb group (PcG), PRC1 and 2 (Polycomb 
Repressive Complex 1 and 2) or Trithorax group (TrxG). This two groups of 
proteins have opposite role in gene regulation. PcG having mainly a repressors 
function while TrxG activates transcription. Because RAIN expression is 
positively associated to RUNX2 expression, we reasoned that its function in 
controlling RUNX2 could be mediated by the interaction with members of the 
TrxG group. Some studies had previously demonstrated the functional 
interaction of WDR5 with other lncRNAs including BLACAT 2 (bladder 
cancer-associated transcript 2) [135], GClnc1 (gastric cancer–associated 
lncRNA 1) [98], HOTTIP (HOXA transcript at the distal tip) [136], HOXD-
AS1 (HOXD antisense 1) [99]. Similarly, we demonstrated that RAIN interacts 
with WDR5 promoting its recruitment to the RUNX2 P2 promoter. The 
interaction between RAIN and WDR5 is functional since silencing of RAIN 
resulted in a marked reduction WDR5 binding on the RUNX2 promoter. As a 
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consequence, the levels of H3K4Me3, H3K27Ac and RNA-PolII binding on the 
RUNX2 promoter was significantly decreased upon RAIN knockdown with a 
consequential effect on RUNX2 transcription. 
Furthermore, we also demonstrated that RAIN interacts with NELFe and 
restrains its binding within the RUNX2 promoter. The idea that ncRNAs could 
also affect elongation was recently proposed based on the evidences that 
eRNAs promote transcription of immediate early genes in neurons without 
affecting chromatin structure [104]. These authors demonstrated that 
sequestering NELFe, eRNAs restrain the binding and the inhibitory function of 
the NELF complex on target genes, promoting RNA-PolII progression and 
elongation. Similarly, we showed that silencing of RAIN increases binding of 
NELFe on the P2 promoter and silencing of NELFe results in increased 
RUNX2 expression. We observed that the decrease of RNA-PolII phospho-S5 
binding was 700bp downstream of the TSS, while the NELFe binding was 
enriched on TSS of RUNX2 and that complied with the stop of initiation of 
transcription. To ensure that the RUNX2 downregulation is due to the NELFe 
binding, we should conduct more experiments to confirm the increase of RNA-
PolII total on TSS and the decrease of RNA-PolII phospho-S2 (marker of late 
stage of transcription) at 3’end of the gene. 
Before our work, the ability of interfering with the NELF complex activity was 
shown only for eRNAs. Thus, at the best of our knowledge, this is the first 
demonstration of a functional interaction between the NELF complex with an 
ENH-associated lncRNA. Furthermore, we can also affirm that this is the first 
evidence that lncRNA can play multiple function in the expression regulation of 
target genes thanks to the interaction with different functional complexes. 
Finally, we provide evidence that RAIN not only affects RUNX2 expression but 
acts also on other targets and through this multiple transcriptional effect 
promote cancer cells phenotype. By performing RNA-Seq on thyroid cancer 
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cells, in which the expression of RAIN was down-regulated, we showed that 
RAIN controls a large panel of genes of which only a fraction (about 20%) 
were co-shared in regulation with RUNX2. By contrast, more than 500 genes 
were differentially regulated selectively after l-RAIN knock-down. Further 
experiments are needed to validate these results and to fully define the l-RAIN 
mechanism of action on these targets. 
 
In conclusion, 1) we found and characterized a novel lncRNA family, 2) we 
functionally proved that RAIN is able to regulate RUNX2 expression through 
two different mechanisms (one of this never characterized before), and 3) we 
provided preliminary evidences that RAIN has additional, RUNX2-
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